Jonathon Li News Today : Breaking News, Live Updates & Top Stories | Vimarsana

<p>A new study by investigators from <a href="https://www.massgeneralbrigham.org/">Mass General Brigham</a> found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test&mdash;a phenomenon known as virologic rebound. By contrast, people not taking Paxlovid only experienced rebound about 2 percent of the time. Results are published in <a href="...

A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test-;a phenomenon known as virologic rebound.

People not taking Paxlovid experienced the viral rebound phenomenon only about two per cent of the time, the researchers at the Mass General Brigham hospital, Boston, US, found. Paxlovid, which is a Nirmatrelvir-ritonavir therapy taken orally, has been previously studied to be effective in reducing hospitalisation and death in severe COVID-19 infections.

A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test—a phenomenon known as virologic rebound.

A study by researchers at Mass General Brigham hospital in Boston found that one in five COVID-infected individuals treated with antiviral medication Paxlovid experienced viral rebound, shedding live and potentially contagious virus after an initial negative test. The rebound phenomenon was more common than expected, occurring over 20% of the time with Paxlovid. The study highlights the need for patient counseling and re-testing during Paxlovid treatment, despite its effectiveness in reducing hospitalization and death in severe COVID-19 cases.